Rabbit Polyclonal CYP2D6 Antibody

The cytochrome P450 2D6 (CYP2D6) antibody is a critical tool for studying the expression and function of the CYP2D6 enzyme, a member of the cytochrome P450 superfamily involved in metabolizing ~25% of clinically used drugs, including antidepressants, antipsychotics, and beta-blockers. CYP2D6 exhibits significant genetic polymorphism, leading to variable enzyme activity (classified as poor, intermediate, extensive, or ultrarapid metabolizers), which impacts drug efficacy and toxicity. Researchers use CYP2D6 antibodies primarily to detect protein levels in tissues (e.g., liver, brain) via techniques like Western blotting, immunohistochemistry (IHC), or ELISA. These antibodies help investigate interindividual variability in drug metabolism, enzyme localization, and regulatory mechanisms. Monoclonal and polyclonal variants are available, often validated for specificity against recombinant or endogenous CYP2D6. Challenges include cross-reactivity with homologous CYP isoforms (e.g., CYP2D7. CYP2D8), necessitating rigorous validation. Applications extend to pharmacogenomics, personalized medicine, and toxicology studies, particularly in assessing drug-drug interactions or enzyme induction/inhibition. Commercially sourced from suppliers like Abcam or Santa Cruz Biotechnology, these antibodies underpin both diagnostic and research efforts to align drug therapies with genetic profiles, optimizing therapeutic outcomes while minimizing adverse effects.